Adam S. Grossman is the CEO of ADMA Biologics, a position he has held since 2011. With over 20 years of experience in the blood and plasma industry, he has a strong background in launching new products and managing sales...

Number of Employees

624

Year

2023

Total Compensation

$4.16M

Salary

$750.00K

Board Justification

The compensation aligns with company performance, peer benchmarking, and retention strategies, with a focus on attracting and retaining top talent.

Bonus

$793.13K

Board Justification

Annual cash bonuses based on performance milestones and objectives established by the Board, paid in March 2024.

Other

$46.80K

Board Justification

Includes employer contributions to 401(k) plan and medical benefits paid by the Company.

Restricted Stock

$2.57M(573.7K RSU)

Board Justification

RSUs granted on March 6, 2023, vesting quarterly over four years, subject to continued service.

Performance Metrics

Performance metrics include achievement of specific financial and operational goals set by the Board.

SEC Filing

From April 15, 2024

Adam S. Grossman

CEO of ADMA Biologics

A

Education

Field of Expertise

Business & Management

Born

Invalid Date - 0 years ago

Is Founder?

No

Current Tenure

8 years 7 months (Jun 2016 - Present)

Previous Experience